Ribavirin is an antiviral medication that works with other medications to treat hepatitis C. This condition is a virus that causes chronic liver inflammation. This medication comes in a tablet form that you can take by mouth with a glass of water. Chemically it is a synthetic guanosine nucleoside analogue, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, that is intracellularly phosphorylated to mono, di and triphosphate metabolites; these metabolites reduce guanosine triphosphate pools by inhibiting inosine monophosphate dehydrogenase and can induce lethal mutagenesis of viral RNA while interfering with viral polymerases. Ribavirin is administered orally for chronic hepatitis C as part of combination regimens with direct acting antivirals, and dosing requires consideration of renal function because active metabolites are renally eliminated; important safety considerations include dose-related hemolytic anemia and absolute contraindication in pregnancy due to teratogenicity and embryocidal effects.
Parent: Ribavirin
Parent: Ribavirin
Typical quality specifications for ribavirin API and finished products identify a small set of related substances and degradation products including the de-ribosylated triazole base (1,2,4-triazole derivatives), the carboxylic acid hydrolysis product, N-oxide or oxidized variants, and trace process-related residues; routine control is performed by validated reversed-phase HPLC with UV detection and confirmed by LC-MS when needed. Typical acceptance criteria applied in many regulatory dossiers are individual known impurities not greater than 0.2 to 0.5 percent by area or weight depending on impurity identification and toxicological qualification, with total impurities generally limited to about 1.0 percent; unspecified impurities are often limited to 0.05 percent or lower. Additional quality attributes include water content meeting pharmacopeial limits, elemental impurities controlled per ICH Q3D, and residual solvents controlled per ICH Q3C, with limits chosen according to solvent class and toxicological guidance.
Ribavirin is a nucleoside analogue that is phosphorylated inside cells to mono, di and triphosphate forms; the monophosphate inhibits inosine monophosphate dehydrogenase thereby depleting GTP pools, while the triphosphate interacts with viral polymerases and increases the viral mutation rate, collectively impairing viral replication.
Ribavirin has been used to treat severe respiratory syncytial virus infections, historically as an aerosolized formulation for high-risk infants and immunocompromised patients, but routine use is limited and current practice reserves it for select severe or high-risk cases based on clinical judgment and institutional protocols.
No, ribavirin is not an antibiotic; it is an antiviral agent that targets viral replication mechanisms rather than bacterial targets.
The most significant and commonly monitored adverse effect is hemolytic anemia, which can be dose limiting and may require dose reduction or discontinuation; additionally, ribavirin is highly teratogenic and contraindicated in pregnancy, requiring strict pregnancy prevention measures for patients and partners of patients of reproductive potential.
